使用基于GE11的新型EGFR特异性Fc融合的向癌症治疗
Malihe Hallaji1, Mojgan Allahyari2, Ladan Teimoori-Toolabi3
1Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.
Scientific reports
|February 11, 2025
概括
Fc融合或体为单克隆抗体提供了一种新的癌症治疗替代方案. 这项研究表明,FcIgG-GE11体有效向并抑制EGFR过度表达的癌细胞.
科学领域:
- 生物技术是生物技术.
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- Fc融合 (体) 正在成为向癌症治疗的新兴药物.
- 单克隆抗体 (mAbs) 是当前的标准,但体具有潜在的优势.
- 表皮生长因子受体 (EGFR) 是许多癌症的关键标.
研究的目的:
- 开发和表征一种针对EGFR的Fc融合.
- 为了评估FcIgG-GE11体的抗癌疗效.
- 为了比较其与已知的EGFR向mAb的Cetuximab的性能,
主要方法:
- 菌体显示器被用来识别GE11 EGFR向性.
- FcIgG-GE11在大肠杆菌中表达,并通过离子交换染色学净化.
- 流细胞计,细胞内ELISA和MTT试验用于表征和疗效评估.
主要成果:
- FcIgG-GE11表现出与EGFR的高度亲和力和特定结合.
- 体有效地抑制了EGFR过度表达的癌细胞生长,这种生长方式取决于剂量和时间.
- FcIgG-GE11诱导癌细胞死亡或循环停止,其疗效与Cetuximab相似.
结论:
- FcIgG-GE11体是EGFR过度表达癌症的强大和特定的治疗候选者.
- 这种体代表了传统单克隆抗体的有希望的替代品.
- 进一步的研究可能将FcIgG-GE11确立为癌症治疗中的一个有价值的工具.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464


